Headquartered in Montreal, Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000-square-foot facility. Leveraging Quebec's low electricity costs, Cannara's facility will produce high-grade hydroponically grown indoor cannabis and cannabis derivative products for the Canadian and international markets. Working with partners from various industries, Cannara will generate licensing revenues, rental revenues and revenue streams from joint venture arrangements leveraging this highly valuable property.

1. CORPORATE PRESENTATION
Last updated December 2018
CSE ticker : LOVE

2. This presentation and the information contained within is confidential, proprietary and for authorized use only. It is being presented to prospective investors solely for such investors’ confidential use,
with the express understanding that, without the prior permission in writing from Cannara Biotech Inc. (“Cannara” or the “Company”), the investor will not copy this document or any portion of it or use
any information contained herein for any purpose other than evaluating a potential investment in securities of Cannara. Under no circumstances are its contents to be reproduced or distributed to the
public, media or potential investors without written authorization. The information contained herein, while obtained from sources believed to be reliable, is not guaranteed as to its accuracy or
completeness.
This presentation contains “forward-looking information” within the meaning of Canadian securities legislation. This information and these statements, referred to herein as “forward-looking
statements” are made as of the date of this presentation or as of the date of the effective date of information described in this presentation, as applicable. Forward-looking statements relate to future
events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, without limitation, statements with respect to; (i) the Company’s
intentions to cultivate and produce a variety of cannabis following receipt of an ACMPR licence; (ii) the Company’s proposed product offerings to consumers and premium brands; (iii) the Company’s use
of proceeds arising out of the private placement; (iv) cost of production; and (v) the total gross proceeds raised under the private placement. Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”,
“plans”, “projects”, “estimates”, “envisages”, “assumes”, “intends”, “strategy”, “goals”, “objectives” or variations thereof or stating that certain actions, events or results “may”, “can”, “could”, “would”,
“might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements.
All forward-looking statements are based on Cannara’s current beliefs as well as various assumptions made by, and information currently available to, it. These assumptions include, without limitation: (i)
the successful receipt of the Company’s ACMPR license in 2019; (ii) the availability and continuity of financing; (iii) the successful receipt by FV Pharma Inc. of an ACMPR license at the Company’s facility
in Québec; and (iv) reasonable contingency requirements.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking
statements will not be achieved or that assumptions do not reflect future experience. We caution readers not to place undue reliance on these forward-looking statements as a number of important
factors could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates assumptions and intentions expressed in such forward-looking
statements. These risk factors may be generally stated as the risk that the assumptions and estimates expressed above do not occur, but specifically include, without limitation, risks relating to general
economic conditions, competition from other market participants, the ability to access capital, the ability to achieve technological development and the speed of such development, risks relating to
intellectual property litigation and regulatory actions, and the risk of fluctuation and variation in actual operating results, which variation may be material. The foregoing list of factors that may affect
future results is not exhaustive.
When relying on our forward-looking statements, readers of this presentation should carefully consider the foregoing factors and other uncertainties and potential events. Cannara does not undertake to
update any forward-looking statement, whether written or oral, that may be made from time to time by Cannara or on behalf of Cannara, except as may be required by law.
2
DISCLAIMER

3. BC
25 AB
7 SK
4
MB
2 ON
62
QC
11
NB
3
NS
3
PEI
1
Forecasted Canadian cannabis market in the first year is $5.8B
3
Quebec has only
11 Licensed Producers
2nd largest consumer market
Cannara poised to capture
a large percentage of the $1.1B
Quebec market
QUEBEC OPPORTUNITY

4. CANNARA AT A GLANCE
4
VERTICALLY
INTEGRATED
producer and
processor
largest indoor
facility in Québec
(625,000 sq. ft.)
PREMIUM BRAND PORTFOLIO
medical, recreational, edibles,
beverages and companion animal
ONE-OF-A-KIND

5. ONE-OF-A-KIND QUEBEC FACILITY
A fully controlled and monitored pharma grade environment
5
625,000 sq. ft.
32 foot ceiling
27 acres land
LARGE ELECTRICAL
Production &
downstream processing
MULTIPURPOSE
Lowest electricity
costs in north america
INDOOR
Superior quality and
yield

6. LARGE CAPACITY
6
>100,000 kg
of premium indoor cannabis at
full capacity
27 acres
(Fully funded)
2019 Q1
15,000 kg
2022
55,000 kg
Phase 3
277,000 ft2
Phase 2
230,000 ft2
Phase 1
105,000 ft2
2020
38,000 kg
2nd floor option

7. INDOOR GREENHOUSE
HARVESTS 5+ <4
INFECTIONS/DISEASE Very low risk At risk
ODOR None Poor control
HUMIDITY Total control Poor
POTENCY/QUALITY Highest Lower
MOLD/MILDEW Low risk High risk
Superior yield, less risk, pharma-grade
INDOOR GROWING IS BETTER
7

8. MULTIPURPOSE FACILITY
8
Multi-purpose facility will be leveraged with leading partners to produce beverages, capsules,
confectionaries and a multitude of other cannabis products.
Scale and Margin Growth
PRODUCTION
500,000 sq. ft.
Cultivation
Trimming
Curing
Extraction
+
PROCESSING
100,000 sq. ft.

9. 9
Local buy-in
Cannabis zoned real estate
Affordable labour force
Lowest energy cost in North America
45 minutes to Montreal
FARNHAM, QUEBEC

10. HOUSE OF BRANDS STRATEGY
10
Classic approach for consumer packaged goods, that delivers
the most brand equity for individual products

11. Web Presence
Forecasted Quebec
Market
Growth in Mature
Markets
www.nativa.com
569M 85M 23M 55M 1.4M
+40% +57% +23% +24% white field
www.cannabar.com
www.gummyz.com
www.brew.ca
www.liquidcbd.com
www.petleaf.com
www.earthmagic.com
www.floragel.com
OUR BRAND PORTFOLIO
RECREATIONAL MEDICINAL
Flowers/Oils Edibles Beverages Humans Pets
8 brands, 1 company

12. 12
1
2
PRODUCT LINES
Flower
Oils
Concentrates
Pre-rolls
Vapes and vape accessories
Cartridges
www.nativa.com
Indoor grown,
premium grade.

13. 13
PRODUCT LINES
Chocolate bars
Granola bars (fruit and nut)
Protein bars
Brownies and cookies
Snack and regular formats
Confections on
another level.
www.cannabar.com

14. 14
1
4
PRODUCT LINES
Candies
Chewables
Gummy candies
Fun that fits
in your pocket.
www.gummyz.com

15. 15
1
5
PRODUCT LINES
Coffees
Teas
Kombuchas
Push your
boundaries.
www.brew.ca

16. 1
6
PRODUCT LINES
CDB infused (non THC)
Water
Vitamin Water
Hydration beverage
16
www.liquidcbd.com
Imagine your zen.

17. Back to our roots.
17
PRODUCT LINES
Topicals
Lip balm
Dermal
www.earthmagic.com

18. The power of the
plant for wellness
beyond measure.
18
PRODUCT LINES
Softgels
Tinctures
www.floragel.com

19. 19
Your pets deserve
natural healing.
PRODUCT LINES
Edibles (pet treats)
Wellness oils
Care products
www.petleaf.com

20. 20
CANNARA’S COLLABORATION CORRIDOR
Joint Ventures in process with product manufacturers for development of cannabis
derivative branded products.
Cannara’s facility will be leveraged to partner
with proven entities allowing for cannabis
infused production on-site, facilitating
manufacturing processes, formulation and
overall speed to market.

21. PARTNERSHIP WITH FV PHARMA
21
Cannara Biotech has signed a partnership agreement with FV
Pharma in order to promote further innovation and to
develop new scientific development in the cannabis space.
FSD Pharma (CSE: HUGE), the parent company of FV Pharma,
is a federally-licensed producer of medical cannabis under
the Access to Cannabis for Medical Purposes Regulations
(ACMPR), operating out of a 620,000 square foot facility
located in Cobourg, Ontario.

22. 22
INTELLECTUAL PROPERTY
PATENTS FILED
8 Dermal
4 Oral
3 Companion Animal
DOMAIN NAMES/
TRADEMARKS
35
Scientific team developing innovative products through
applied research and development
Rapid onset
Topical
Formulations
Precise dosing
Micro dosing
15 R&D

23. CANNARA’S GROW TEAM
23
Cannara has assembled a team of cannabis growing leaders with 50+
years of MMAR & MMPR experience. Their expertise in indoor system
design, production, nutrition and crop management has been
illustrated through average yields of 3 lbs per light.

24. MANAGEMENT TEAM
24
ZOHAR KRIVOROT
CEO & Founder
Successful entrepreneur. Founded, and sold
numerous companies, including 911ENABLE™
which he led from start-up to its acquisition
by West Telecom in 2014. Recognized
by Deloitte Technology Fast 50™
LENNIE RYER CPA, CA
Chief Financial Officer
Designed and executed multiple treasury
and secondary offerings in excess of $450
million as CFO for private and public
companies.
EVAN MORRIS
Chief Operating Officer
Helped transform a fledgling casino
technology start-up with only a handful of
employees, into the largest online gambling
company on the planet in just over four
years.
ALEX WOLFE
VP Business Development
Long-standing believer and advocate for
legal cannabis. 10 years of experience in
sales and business development within
regulated industries, including liquor sales
and marketing.
JULIA BOUVET
Chief of Staff
Business strategist who has advised Fortune
500 companies such as Walmart, Kraft Foods,
P&G, Best Buy, Hershey’s, Kellogg’s and
McKesson. Named one of Canada’s top 150
influential women.
DR. MICHAEL LIVERMAN
Chief Science Officer C.S.O.
A medical professional with
degrees from McGill University
and with 40 years of expertise. He is a long
time advocate of medical cannabis and sees
the numerous possibilities for its use in both
the medical and dental domains.

25. 25
lennie@cannara.ca
1 514-913-9136
Lennie Ryer CPA, CA
CFO, VICE PRESIDENT
alex@cannara.ca
1 514-222-4237
Alex Wolfe
VP, BUSINESS DEVELOPMENT
INVESTMENT INQUIRIES BUSINESS INQUIRIES
www.cannara.ca
CONTACT